Patent application number | Description | Published |
20100137400 | PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof. | 06-03-2010 |
20100196469 | Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof - The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression. | 08-05-2010 |
20100297225 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF - The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof. | 11-25-2010 |
20110033538 | Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation. | 02-10-2011 |
20110065751 | Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation. | 03-17-2011 |
20140187520 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF VITAMIN D RECEPTOR AGONIST AND PROCESS FOR PREPARATION THEREOF - The present invention relates to a stable pharmaceutical composition for intravenous administration comprising a Vitamin D receptor agonist, particularly paricalcitol, and a process of preparation thereof. | 07-03-2014 |
20140235656 | SUBLINGUAL PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIHISTAMINE AGENT AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof. | 08-21-2014 |
20150080385 | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a stable pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brinzolamide or ophthalmologic acceptable salts thereof and an effective quantity of a surfactant such as poloxamer, to be used for the treatment of ocular hypertension and glaucoma. | 03-19-2015 |